Hepatology International

, Volume 13, Issue 2, pp 214–221 | Cite as

Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd–Chiari syndrome on warfarin

  • Akash ShuklaEmail author
  • Abhinav Jain
  • Vinit Kahalekar
  • Sheetal Bendkhale
  • Nithya Gogtay
  • Urmila Thatte
  • Shobna Bhatia
Original Article



Anticoagulation is universally recommended in Budd–Chiari syndrome [BCS]. Vitamin K epoxide reductase complex 1 (VKORC1) and CYP2C9 are involved in the metabolism of warfarin. The present study was done to assess whether these mutations are associated with the risk of bleeding in patients with BCS receiving warfarin.

Patients and methods

Patients diagnosed with BCS underwent genotyping for three single nucleotide polymorphisms [SNPs]—two for the CYP2C9 and one for the VKORC1 haplotype. The patients were followed up for at least 12 months and all bleeding episodes were recorded. Patients with and without mutations were compared for bleeding complications and a crude odds ratio [crude OR] was derived for the association between bleeding and presence or absence of mutant alleles.


Eighty patients [mean (SD) age 27.47 (8.93) years, 35 male] with BCS underwent genetic testing. 37/80 (46.2%) patients had mutation of CYP2C9 and/or VKORC1; 22/80 (27.5%) had either of the mutant alleles of CYP2C9 and, similarly, 22/80 (27.5%) had the VKORC mutation. Over a median follow-up of 20 (range 12–96) months, 21/80 (26.3%) patients had bleeding complications. Patients with mutant SNPs had a higher risk of bleeding than those without [14/37 vs. 7/43, p = 0.04, crude OR (95% CI) 3.13 (1.1–8.9)].


The presence of mutations in VKORC1 or CYP2C9 is associated with increased risk of bleeding in patients with BCS on warfarin. Such patients with SNPs of CY2C9 or VKORC1 haplotype should be monitored intensively while receiving warfarin.


Portal hypertension Varices Anticoagulation Cirrhosis Hemorrhage Hepatic venous outflow tract obstruction 



Budd–Chiari syndrome


Model for end-stage liver disease


Single nucleotide polymorphisms


Transjugular intrahepatic portacaval shunt


Vitamin K epoxide reductase complex 1


Author Contributions

SA: conceptualized the study, protocol development, data collection, data interpretation, writing manuscript. JA: data collection, data analysis, writing manuscript. KV: data analysis, writing manuscript. BS: protocol development, laboratory work. GN: protocol development, supervision of laboratory work, data analysis and interpretation, writing manuscript. TU: protocol development, supervision of laboratory work, data interpretation, approval of manuscript. BS: protocol development, supervision of data collection, data interpretation, approval of manuscript.

Compliance with ethical requirements

Conflict of interest

Akash Shukla, Abhinav Jain, Vinit Kahalekar, Shital Bendkhale, Nithya Gogtay, Urmila Thatte and Shobna Bhatia have no conflict of interest to declare.

Informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study.


  1. 1.
    Horton JD, San Miguel FL, Membreno F, et al. Budd–Chiari syndrome: illustrated review of current management. Liver Int. 2008;28:455–66.CrossRefGoogle Scholar
  2. 2.
    Zhang C, Gu V, Zhu G, Luo T, Yan C, Wang Z. Hybrid treatment for Budd–Chiari syndrome—a case report by 11-year follow up. Ann Vasc Surg. 2017;38(e1–319):e6.Google Scholar
  3. 3.
    Valla DC. Primary Budd–Chiari syndrome. J Hepatol. 2009;50:195–203.CrossRefGoogle Scholar
  4. 4.
    Bogin V, Marcos A, Shaw-Stiffel T. Budd–Chiari syndrome: in evolution. Eur J Gastroenterol Hepatol. 2005;17:33–5.CrossRefGoogle Scholar
  5. 5.
    Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008;83:312–21.CrossRefGoogle Scholar
  6. 6.
    Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012;7:e44064.CrossRefGoogle Scholar
  7. 7.
    Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol. 2011;57:612–8.CrossRefGoogle Scholar
  8. 8.
    Gage BF, Eby C, Johnson JA, Deych E, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326–31.CrossRefGoogle Scholar
  9. 9.
    International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753–64.CrossRefGoogle Scholar
  10. 10.
    Plessier A, Valla DC. Budd–Chiari syndrome. Semin Liver Dis. 2008;28:259–69.CrossRefGoogle Scholar
  11. 11.
    Montano-Loza AJ, Tandon P, Kneteman N, Baily R, Bain VG. Rotterdam score predicts early mortality in Budd–Chiari syndrome, and surgical shunting prolongs transplant free survival. Aliment Pharmacol Ther. 2009;30:1060–9.CrossRefGoogle Scholar
  12. 12.
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71.CrossRefGoogle Scholar
  13. 13.
    Flockhart DA, O’Kane D, Williams MS, ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10:139–50.CrossRefGoogle Scholar
  14. 14.
    COUMADIN-Warfarin Sodium Tablet) [package insert]. Princeton: Bristol-Myers Squibb Pharma Company; 2015. Available from: Accessed 20 Apr 2018.
  15. 15.
    Sridharan K, Modi T, Bendkhale S, Kulkarni D, Gogtay NJ, Thatte UM. Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: a case-control study. Curr Clin Pharmacol. 2016;11(1):62–8.CrossRefGoogle Scholar
  16. 16.
    De Franchis R, Baveno VI faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52.CrossRefGoogle Scholar
  17. 17.
    Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.CrossRefGoogle Scholar
  18. 18.
    Sandén P, Renlund H, Svensson PJ, Själander A. Bleeding complications in venous thrombosis patients on well-managed warfarin. J Thromb Thrombolysis. 2016;41(2):351–8.CrossRefGoogle Scholar
  19. 19.
    do Delga MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis1. Clin Gastroenterol Hepatol. 2012;10:776–83.CrossRefGoogle Scholar
  20. 20.
    Darwish MS, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd–Chiari syndrome. Ann Intern Med. 2009;151:167–75.CrossRefGoogle Scholar
  21. 21.
    Seijo S, Plessier A, Hoekstra J, et al. Good long term outcome of Budd–Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–8.CrossRefGoogle Scholar
  22. 22.
    Shukla A, Bhatia SJ. Outcome of patients with primary hepatic venous obstruction treated with anticoagulants alone. Indian J Gastroenterol. 2010;29(1):8–11.CrossRefGoogle Scholar
  23. 23.
    Pasmant E, de Beauvoir C, Plessier A, Labreuche J, Bezeaud A. VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis. Thromb Res. 2010;126(2):e134–6.CrossRefGoogle Scholar
  24. 24.
    Benusiglio PR, Desmeules J, de Moerloose P, Dayer P. Oral anticoagulation and pharmacogenetics: importance in the clinical setting. Rev Med Suisse. 2007;3(124):2030 (2033-4, 2036).Google Scholar
  25. 25.
    Adithan C, Gerard N, Vasu S, Balakrishnan R, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol. 2003;59:707–9.CrossRefGoogle Scholar
  26. 26.
    Shalia K, Doshi SM, Parikh S, et al. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response. JAPI. 2012;60:34–8.Google Scholar
  27. 27.
    Pirmohamed M, Burnside G, Eriksson N, EU-PACT Group, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303.CrossRefGoogle Scholar
  28. 28.
    Kimmel SE, French B, Kasner SE, COAG Investigators, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–93.CrossRefGoogle Scholar
  29. 29.
    Johnson JA, Caudle KE, Gong L, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397–404.CrossRefGoogle Scholar
  30. 30.
    Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–56.CrossRefGoogle Scholar
  31. 31.
    Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–77.CrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2019

Authors and Affiliations

  1. 1.Department of GastroenterologySeth GS Medical College and KEM HospitalMumbaiIndia
  2. 2.Department of Clinical PharmacologySeth GS Medical College and KEM HospitalMumbaiIndia

Personalised recommendations